- Details
- Description
Packaging Size:
21T/Bottle
Strength:
30mg&90mg
Composition:
Brigatinib
Treatment:
ALK+ non-small cell lung cancer (NSCLC)
Form:
Tablet
Brand:
Beigani
Quantity Unit:
30mg&90mg*21T/bottle
Manufacturer:
Tongmeng (Lao) Pharmaceutical & Food Co., Ltd.（TLPH）
Brigatinib is a targeted cancer drug treatment for non small cell lung cancer (NSCLC). It is also known as Alunbrig. It is a treatment for a type of lung cancer called non small cell lung cancer (NSCLC) that has spread to other parts of the body (advanced or metastatic NSCLC).
Non-Small Cell Lung Cancer
Indicated for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) 90 mg PO qDay for the first 7 days; if 90 mg/day tolerated, increase to 180 mg PO qDay Continue until disease progression or unacceptable toxicityDosage Modifications
If treatment is interrupted for ≥14 days for reasons other than adverse reactions, resume at 90 mg qDay for 7 days before increasing to previously tolerated doseDose reductions
Once discontinued, do not subsequently increase dose Permanently discontinue if unable to tolerate 60 mg/day-
90 mg/day dose
- First reduction: 60 mg qDay
-
180 mg/day dose
- First reduction: 120 mg qDay
- Second reduction: 90 mg qDay
- Third reduction: 60 mg qDay
